Recent 8-K filings for NRIX

• July 9, 2026, 4:09 PM ET M&A materiality 0.90 positive item 2.02item 9.01

  Nurix enters $2.3B Roche collaboration for bexobrutideg; Q2 net loss $89.5M

  Global collaboration with Roche for bexobrutideg: $700M upfront, up to $2.3B total; co-dev/co-commercialization in hematology, immunology, neurology.

• June 11, 2026, 7:06 AM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line

  Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.

• June 8, 2026, 6:11 AM ET other material materiality 0.90 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total

  Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.

• April 8, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program

  Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).

• January 28, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg

  FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM

  Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.

• December 9, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025

  Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.

• October 22, 2025, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Nurix raises $250M in registered offering; shares priced at $10.21

  Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.

• October 22, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose

  DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.

• October 9, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track

  Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.

• September 3, 2025, 7:59 PM ET other material materiality 0.65 neutral item 7.01item 9.01

  Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial

  Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.

• July 9, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL

  Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.

• June 12, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025

  ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.

• April 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation

  Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.

• January 28, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%

  Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.

• January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025

  Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.

• December 10, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025

  ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.

• October 11, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M

  Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.

• July 11, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 8.01item 9.01

  Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL

  Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).

• June 17, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025

  Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.

• April 12, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share

  10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.

• April 10, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended

  Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.

• April 9, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Nurix announces first clinical responses in brain for BTK degrader NX-5948

  NX-5948 detected in CSF from all available samples, showing brain penetration.

• March 11, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume

  FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.

• February 15, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold

  FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.

• January 8, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  Nurix Therapeutics outlines 2024 priorities: BTK degrader NX-5948 acceleration, partial hold on NX-2127

  Positive Phase 1 data for NX-5948 (BTK degrader) in CLL/NHL; plans to accelerate enrollment toward pivotal trials.

• December 11, 2023, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023

  NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.

• November 1, 2023, 7:59 PM ET regulatory materiality 0.75 negative item 8.01item 9.01

  FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused

  FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.

• October 12, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q3 FY2023 revenue $18.5M, net loss $37.0M; Seagen collaboration yields $60M upfront

  Revenue of $18.5M, up 71% YoY, driven by $8M in research milestones from Gilead and Sanofi.

• September 7, 2023, 7:59 PM ET other material materiality 0.90 positive item 1.01 ◈ Material Agreements

  Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs

  Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.

• July 13, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license

  Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.

• April 13, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Nurix licenses IRAK4 degrader to Gilead for $20M; Q1 net loss $40.7M

  Gilead exercised option to license NX-0479/GS-6791, triggering $20M payment; up to $425M in milestones plus tiered royalties up to low double-digits.

• April 10, 2023, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change

  Nurix Therapeutics COO Stefani A. Wolff resigns, effective May 2, 2023

  Stefani A. Wolff notified resignation as COO and EVP of Product Development on April 5, 2023.

• February 9, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL

  Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.

• January 9, 2023, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference

  NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.

• December 13, 2022, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL

  ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

26 positive 2 negative 22 neutral

source · NRIX on sec.gov